Testing targeted therapies in cancer using structural dna alteration analysis and patient-derived xenografts

Piyan Zhang, Irina V. Kovtun

Research output: Contribution to journalArticle

Abstract

We present here an integrative approach for testing efficacy of targeted therapies that combines the next generation sequencing technolo-gies, therapeutic target analyses and drug response monitoring using patient derived xenografts (PDX). This strategy was validated using ovarian tumors as an example. The mate-pair next generation sequencing (MPseq) protocol was used to identify structural alterations and followed by analysis of potentially targetable alterations. Human tumors grown in immunocompromised mice were treated with drugs selected based on the genomic analyses. Results demonstrated a good correlation between the predicted and the observed responses in the PDX model. The presented approach can be used to test the efficacy of combination treatments and aid personalized treatment for patients with recurrent cancer, specifically in cases when standard therapy fails and there is a need to use drugs off label.

Original languageEnglish (US)
Article numbere60646
Pages (from-to)1-19
Number of pages19
JournalJournal of Visualized Experiments
Volume2020
Issue number161
DOIs
StatePublished - Jul 2020

ASJC Scopus subject areas

  • Neuroscience(all)
  • Chemical Engineering(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'Testing targeted therapies in cancer using structural dna alteration analysis and patient-derived xenografts'. Together they form a unique fingerprint.

  • Cite this